Andrew Bellinger - 01 Dec 2022 Form 4 Insider Report for Verve Therapeutics, Inc. (VERV)

Role: CSO & CMO
Signature: /s/ Andrew Ashe, as Attorney-in-Fact for Andrew Bellinger
Issuer symbol: VERV
Transactions as of: 01 Dec 2022
Net transactions value: -$19,852
Form type: 4
Filing time: 02 Dec 2022, 16:00:32 UTC
Previous filing: 01 Nov 2022
Next filing: 16 Dec 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VERV	Common Stock	Sale	$19,852	-865	-12%	$22.95	6,629	01 Dec 2022	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares acquired pursuant to the Verve Therapeutics, Inc. Amended and Restated 2021 Employee Stock Purchase Plan on November 30, 2022 in a transaction exempt pursuant to Rule 16b-3(c). The shares were automatically sold through an automatic sale program in which the Reporting Person elected to participate on May 1, 2022. The sale does not represent a discretionary trade by the Reporting Person.

Content

Represents shares acquired pursuant to the Verve Therapeutics, Inc. Amended and Restated 2021 Employee Stock Purchase Plan on November 30, 2022 in a transaction exempt pursuant to Rule 16b-3(c). The shares were automatically sold through an automatic sale program in which the Reporting Person elected to participate on May 1, 2022. The sale does not represent a discretionary trade by the Reporting Person.